Industry Insights
The global Transfection Reagent & Equipment Market size is
estimated to reach USD 1.08 billion by 2022, exhibiting a 7.4% CAGR during the
forecast period. The primary factor for the growth of this segment is the
rising demand for the production of the recombinant protein.
Advancements in the clinical development of biopharmaceuticals,
is anticipated to boost the demand for gene analysis and gene expression studies
for the purpose of bio-authenticity and investigative analysis. The
aforementioned factor is attributive to drive the segment revenue potentially
in the coming years.
Patent cliff generated in recent years is pronouncing the need
for production of several moieties which depends on the laboratory analysis
thus inducing industrial growth in this market. Anticipated rise in the
analytical methods is expected to increase the adoption of such technologies in
the coming years.
Request Sample Copy of This Market Research @
Additionally, with established healthcare infrastructure and
reimbursement policy, many pharma companies are expanding their business in
western geographic segments which would induce innovation and growth in the
biotechnology industry over the forecasted period.
Method Insights
Electroporation method for conducting transfection process holds
the largest share of the revenue. The larger share is attributive to its
diverse versatility in application, user-friendliness, and consequent higher
implementation of this technique. However, the misuse of this method has caused
cell damage which is expected to slow down its adoption.
Liposomal method is second only to the electroporation method of
transfection. The other segments for the implementation of method includes
adenoviral vectors and particle bombardment which are expected to provide
positive growth in the forecasted period.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/transfection-reagents-equipment-market
Bombardment equipment and particle acceleration have witnessed a
reduction in the cost over the past years which will boost its market
penetration. This method is expected to grow at the fastest rate owing to
increasing investment in order to bring about technological innovations in this
market.
Application Insights
Gene expression accounted for the largest share of revenue in
2016 as a result of larger use of the technology in this segment. Vaccine
biopharmaceuticals production requires substantial usage of gene expression
methods based on the principles of transfection.
Proteomic analyzers and cytology-based programs (for research
purpose) are expected to witness demand in biomedical and oncology studies.
This factor is expected to fuel progress in the coming years.
Regional Insights
North American region witnessed highest penetration in 2016
owing to the presence of large number of research and biopharmaceutical production
institutes, biosimilar drugs, vaccines, and clinical organizations for R&D.
With the rise in number of academic institutes engaged in basic
research for protein and genetic research which are highly supported by the
government, the market revenue for transfection is anticipated to witness
potential increment. Also, a large number of cancer research and specialized
biomedical institute provides a platform for the development of this
technology.
Europe with respect to market share is close to North America
and has gained significantly high revenue as per the estimation. With favorable
government policy, large-scale gene expression analysis is widely implemented
in this region. Also, large-scale development in reverse transfection has
provided a strong base for penetration of the products in this region.
Asia-Pacific region is expected to witness fastest growth over
the forecast period owing to progress in healthcare infrastructure, for
example, setting up of bio-incubators for research purpose, rise in government
funding for basic research held in academic institutions, increasing adoption
of proteomics and cytological expression.
Competitive Insights
Roche, Promega and Life Technologies (a subsidiary of Thermo
Fisher) are renowned players operating in this market. These players are
engaged in implementing strategic initiatives such as product development,
diversification, vertical and horizontal integration, and in some cases
divestiture.
Other companies that are operating in this market are Lonza,
Qiagen, Mirus Bio LLC, OriGene Technologies, EMD Millipore, VWR International,
BTX and SignaGen Laboratory.
Comments
Post a Comment